des-nitro NCX 139

des-nitro NCX 139 is the des-nitro analog derivative of NCX 139, a compound originally developed to lower intraocular pressure (IOP) through dual mechanisms: prostaglandin-F (FP) receptor activation and nitric oxide (NO) release[1][4]. NCX 139 itself comprises latanoprost amide and a NO-donating moiety. Unlike NCX 139, the des-nitro analog lacks the NO-donating functionality. In preclinical studies, des-nitro NCX 139 was used as a comparator and found to be significantly less effective than NCX 139 in reducing IOP, indicating that removal of the NO-donating group eliminated the NO-mediated vascular relaxant effect[1][4]. As such, des-nitro NCX 139 chiefly acts as a prostaglandin analog without NO-mediated effects. There is no evidence it has been developed or marketed independently for clinical use.

Brand names

des-nitro NCX 139

Other names

des-nitro analog of NCX 139